CD4 News and Research

RSS

Study investigates effect of anti-CD45 RIT lymphodepletion on immune cell types

Oncotarget recently published "Targeted lymphodepletion with a CD45-directed antibody radioconjugate as a novel conditioning regimen prior to adoptive cell therapy" which reported that Chimeric antigen receptor T cell therapies, and adoptive cell therapy in general, represent one of the most promising anti-cancer strategies.

12 Jan 2021

The mystery of Giglio island’s resistance to COVID-19

An intriguing new study explores the mechanisms by which an Italian island called Giglio remained resistant to coronavirus disease 2019 (COVID-19) even after much exposure.

11 Jan 2021

Severe COVID-19 recovered patients do not display long-lasting adaptive immune responses, finds study

A team of scientists from the University of Valencia and INCLIVA Health Research Institute, Spain, has recently investigated the durability of immune responses specifically developed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19).

7 Jan 2021

Adaptive immune system against COVID-19 can last for at least eight months

New data suggest that nearly all COVID-19 survivors have the immune cells necessary to fight re-infection.

6 Jan 2021

Scientists develop a new method to study the molecular characteristics of T cells

UT Southwestern scientists have developed a new method to study the molecular characteristics of T cells, critical immune cells that recognize and attack invaders in the body such as viruses, bacteria, and cancer.

6 Jan 2021

Researchers identify the missing link between intestinal disease and brain injury in premature infants

Physicians have long known that necrotizing enterocolitis (NEC), a potentially lethal inflammatory condition that destroys a premature infant's intestinal lining, is often connected to the development of severe brain injury in those infants who survive.

6 Jan 2021

Sustained immune dysregulation due to COVID-19 in non-hospitalized patients

COVID-19, which has killed 1.7 million people worldwide, does not follow a uniform path.

29 Dec 2020

Could engineered red blood cells be an effective antiviral against SARS-CoV-2?

In a new study, released on the bioRxiv* preprint server, a team of researchers explores the antiviral potential of red blood cells against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of COVID-19.

24 Dec 2020

Immunologic modeling of COVID-19 severity and chronicity

In a new study by researchers at Universidad de Costa Rica and other institutions, a bioinformatics approach is used to determine whether Chronic COVID-19 (CC) might have a distinct immunologic signature compared to the mild to moderate (MM) or the severe/critical COVID-19.

24 Dec 2020

Cell-mediated immunity may be more important than neutralizing antibodies in COVID-19 outcome

A new study sheds light on some important differences between asymptomatic and symptomatic patients with coronavirus disease 2019 (COVID-19).

23 Dec 2020

Researchers demonstrate potential preventive treatment for Crohn's disease

A potential preventive treatment for Crohn's disease, a form of inflammatory bowel disease, has been demonstrated in a mouse model and using immune-reactive T cells from patients with Crohn's disease.

21 Dec 2020

Researchers identify new immune cell that acts as major driver of breast cancer growth

Breast cancer is the most common cancer in women worldwide, but many immunotherapies have had limited success in treating aggressive forms of the disease.

16 Dec 2020

Epitope “megapools” could help determine role T cell immunity plays in COVID-19

Researchers in the United States and Australia have conducted a comprehensive analysis of the epitope recognition patterns associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in humans.

14 Dec 2020

Recovered COVID-19 patients exhibit persistent cellular immunity

Researchers at The Rockefeller University in New York have conducted a study showing that infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – triggers persistent T cell responses that last for at least six months.

14 Dec 2020

Study shows how STAT5 optimizes function of CD4+ T cells to drive antitumor immunity

Cancer immunotherapy using "designer" immune cells has revolutionized cancer treatment in recent years. In this type of therapy, T cells, a type of white blood cell, are collected from a patient's blood and subjected to genetic engineering to produce T cells carrying a synthetic molecule termed chimeric antigen receptor (CAR) that is designed to enable T cells to recognize and destroy cancer cells.

14 Dec 2020

Reverse phenotyping shows reactive T cell profiles in SARS-CoV-2 infection

A new study appearing as a preprint on the medRxiv* browser in December 2020 employs reverse phenotyping technology to explore T cell responses in COVID-19.

10 Dec 2020

FASLG gene may drive cytokine-linked adverse COVID-19 outcomes with age

A new study published on the preprint server bioRxiv in December 2020 reveals the role played by certain genetic factors in this group, in particular the FASLG gene belonging to the tumor necrosis factor (TNF) family.

8 Dec 2020

A new potential COVID-19 vaccine candidate: YF-S0

A recent study published in the journal Nature describes the safety and efficacy of a live-attenuated yellow fever 17D (YF17D) vector-based vaccine candidate expressing a non-cleavable form of the spike protein of severe acute respiratory coronavirus 2 (SARS-CoV2).

2 Dec 2020

Researchers successfully edit SIV virus from genomes of non-human primates

Taking a major step forward in HIV research, scientists at the Lewis Katz School of Medicine at Temple University have successfully edited SIV - a virus closely related to HIV, the cause of AIDS - from the genomes of non-human primates.

1 Dec 2020

Virus induced lymphocytes show promise for COVID-19 and future pandemics

Researchers in the United States have conducted a study demonstrating the potential of a novel therapeutic approach to treating coronavirus disease 2019 (COVID-19). The therapy augments the body’s T cell response to the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by providing a boost of rapidly expanded virus-specific T cells.

30 Nov 2020